sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_2983> biolink:category biolink:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_2983> ;
    rdf:predicate biolink:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00384> ;
    a rdf:Statement ;
    rdfs:label "\"Anuria. Severe or progressive kidney disease or dysfunction, with the possible exception of nephrosis. Severe hepatic disease. Hypersensitivity to the drug or any of its components. Triamterene capsules should not be used in patients with pre-existing elevated serum potassium, as is sometimes seen in patients with impaired renal function or azotemia, or in patients who develop hyperkalemia while on the drug. Patients should not be placed on dietary potassium supplements, potassium salts or potassium-containing salt substitutes in conjunction with triamterene capsules. Triamterene capsules should not be given to patients receiving other potassium-sparing agents, such as spironolactone, amiloride hydrochloride, or other formulations containing triamterene. Two deaths have been reported in patients receiving concomitant spironolactone and triamterene capsules or Dyazide (r) Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including triamterene capsules. Hyperkalemia is more likely to occur in patients with renal impairment and diabetes (even without evidence of renal impairment), and in the elderly or severely ill. Since uncorrected hyperkalemia may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients receiving triamterene capsules, when dosages are changed or with any illness that may influence renal function.\"" ;
    biolink:provided_by <https://w3id.org/um/NeuroDKG> ;
    biolink:relation schema:MedicalContraindication .
  <https://identifiers.org/drugbank:DB00384> biolink:category biolink:Drug .
}